Cell & Gene Therapy Manufacturing Services Market - Top Companies and Manufacturers

  • Report ID: 6699
  • Published Date: Nov 15, 2024
  • Report Format: PDF, PPT

Companies Dominating the Cell & Gene Therapy Manufacturing Services Landscape

    One of the key strategies adopted by the companies in the cell & gene therapy manufacturing services market is investing in capacity expansion. This is majorly done through building new facilities or upgrading existing ones to accommodate high-demand gene and cell therapy projects.  In January 2023, FUJIFILM Irvine Scientific, Inc. launched the BalanCD HEK293 Viral Feed, which is intended to enhance AAV production for gene therapy applications and viral vector-based vaccines. These launches, in addition to other strategic activities, including geographical expansion, and partnerships between firms are projected to influence positive significant market activities, maintaining healthy competition between the players. Some of the prominent players are:

    • Boehringer Ingelheim International GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bluebird Bio, Inc.
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • Merck KGaA
    • Miltenyi Bioindustry (Miltenyi Biotec)
    • Samsung Biologics
    • Thermo Fisher Scientific Inc
    • WuXi AppTec Co., Ltd.

Browse Key Market Insights with Data Illustration:

In the News

  • In September 2024, Samsung Biologics announced the launch of innovative development platforms named S-AfuCHO, and S-OptiCharge, at BioProcess International 2024.
  • In December 2023, FUJIFILM Corporation invested USD 200 million in two subsidiaries to expand its capability of global cell therapy contract development and manufacturing (CDMO). The investment will fund the new 175,000 sq. ft headquarters of FUJIFILM Cellular Dynamics’ in the U.S.

Author Credits:  Radhika Pawar


  • Report ID: 6699
  • Published Date: Nov 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the cell & gene therapy manufacturing services market was over USD 7.2 billion.

The market size for the cell & gene therapy manufacturing services market is projected to reach USD 58.6 billion by the end of 2037 expanding at a CAGR of 19.1% during the forecast period i.e., between 2025-2037.

The major players in the market are Bluebird Bio, Inc., Catalent, Inc., Charles River Laboratories International, Inc., Merck KGaA, Miltenyi Bioindustry (Miltenyi Biotec), and others.

In terms of mode segment, the contract manufacturing segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 38.9% by the end of 2037 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample